Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Slides:

Advertisements

Similar presentations

Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148

Advertisements

Our bold approach to life-changing medicines

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

Randomized Phase II Trial of Erlotinib (E) Alone or in Combination with Carboplatin/Paclitaxel (CP) in Never or Light Former Smokers with Advanced Lung.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma O’Day S et al. Proc ASCO 2010;Abstract 4. Hodi FS et al. Proc ASCO 2010;Abstract.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

RANDOMIZED PHASE II TRIAL COMPARING FOLFIRINOX (5FU/LEUCOVORIN, IRINOTECAN AND OXALIPLATIN) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Schwartz 44 yo woman with 4 mo hx of abdominal pain –Imaging = pancreatic.

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

FOLFIRINOX: The Obvious Choice Jordan D. Berlin, M.D. Ingram Professor of Cancer Research Co-director, GI Oncology Director, Phase I Research Vanderbilt-Ingram.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Axel Grothey, MD Professor of Oncology Mayo Clinic Rochester, Minnesota Strategies to Improve Patient Outcomes in Gastric and Gastroesophageal Junction.

O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.

Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.

Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Results from a Randomized Phase III Trial of Decitabine versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed.

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.

Gajria D et al. Proc SABCS 2010;Abstract P

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Vahdat L et al. Proc SABCS 2012;Abstract P

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Case presented by Dr Schwartz

Swain SM et al. Proc SABCS 2012;Abstract P

The Nurse View.

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.

PRODIGE 24/CCTG PA.6: Phase III Trial of Adjuvant mFOLFIRINOX vs Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma CCO Independent.

Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: a clinical experience Silvia Vecchiarelli Istituto di Ematologia e Oncologia “L.& A. Serágnoli”,

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.

Coiffier B et al. Proc ASH 2010;Abstract 857.

National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00.

1University Hospital Gasthuisberg, Leuven, Belgium;

Presentation transcript:

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00 PM – 9:30 PM San Francisco, California Moderator Neil Love, MD Eileen M O’Reilly, MD Eric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Polkinghorn 22 yo woman, married, teacher 7/2010: Abdominal pain  workup reveals cystic mass in pancreas and multiple hepatic lesions –Biopsy = pancreatic adenocarcinoma –FOLFIRINOX - no response, substantial toxicity Switched to gemcitabine and erlotinib –Again, substantial toxicity –Scans are “stable” in pancreas and liver mets, small  in spleen lesions BRCA testing - negative

Copyright © 2011 Research To Practice. All rights reserved.

Case presented by Dr Polkinghorn 22 yo woman, married, teacher 7/2010: Abdominal pain  workup reveals cystic mass in pancreas and multiple hepatic lesions –Biopsy = pancreatic adenocarcinoma –FOLFIRINOX - no response, substantial toxicity Switched to gemcitabine and erlotinib –Again, substantial toxicity –Scans are “stable” in pancreas and liver mets, small  in spleen lesions BRCA testing - negative

Copyright © 2011 Research To Practice. All rights reserved. Randomized Phase III Trial Comparing FOLFIRINOX versus Gemcitabine as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma: Preplanned Interim Analysis Results of the PRODIGE 4/ACCORD 11 Trial Conroy T et al. Proc ASCO 2010;Abstract 4010.

Copyright © 2011 Research To Practice. All rights reserved. Conroy T et al. Proc ASCO 2010;Abstract Efficacy Parameter FOLFIRINOX (n = 171) Gemcitabine (n = 171) Hazard ratio (p-value) Disease control rate (CR + PR + SD) 70.2% (0.6% + 31% %) 50.9% (0% + 9.4% %) — (0.0003) Progression15.2%34.5%— Progression-free survival 6.4 months3.3 months 0.47 (<0.0001) Overall survival11.1 months6.8 months 0.57 (<0.0001) FOLFIRINOX recommended as new standard of care for metastatic pancreatic cancer with bilirubin <1.5 ULN and PS 0-1 PRODIGE 4/ACCORD 11: Efficacy Median follow-up: 26.6 months

Copyright © 2011 Research To Practice. All rights reserved. AE (% per patient) FOLFIRINOX (n = 167) Gemcitabine (n = 169)p-value Febrile neutropenia Thrombocytopenia Peripheral neuropathy Vomiting Diarrhea ALT FOLFIRINOX regimen is more toxic, but toxicity is manageable PRODIGE 4/ACCORD 11: Selected Grade 3/4 Adverse Events (AE) Conroy T et al. Proc ASCO 2010;Abstract 4010.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current Cases of Gastrointestinal Cancer Friday, January 21, :00 PM – 9:30 PM San Francisco, California Moderator Neil Love, MD Eileen M O’Reilly, MD Eric Van Cutsem, MD, PhD Andrew X Zhu, MD, PhD Charles D Blanke, MD David Cunningham, MD Steven A Curley, MD

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Polkinghorn 22 yo woman, married, teacher 7/2010: Abdominal pain  workup reveals cystic mass in pancreas and multiple hepatic lesions –Biopsy = pancreatic adenocarcinoma –FOLFIRINOX - no response, substantial toxicity Switched to gemcitabine and erlotinib –Again, substantial toxicity –Scans are “stable” in pancreas and liver mets, small  in spleen lesions BRCA testing - negative

Copyright © 2011 Research To Practice. All rights reserved. A phase II trial of nab-paclitaxel in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy Hosein JP et al. Proc ASCO 2010;Abstract 4120.

Copyright © 2011 Research To Practice. All rights reserved. Hosein PJ et al. Proc ASCO 2010;Abstract 4120 Nab-paclitaxel monotherapy after gemcitabine based therapy Efficacy (n = 19) Time point (months)PFSOS 331.6%73.7% 615.8%57.9% 95.3%47.4% 125.3%36.8% Median1.6 months7.3 months

Copyright © 2011 Research To Practice. All rights reserved. Case presented by Dr Polkinghorn 22 yo woman, married, teacher 7/2010: Abdominal pain  workup reveals cystic mass in pancreas and multiple hepatic lesions –Biopsy = pancreatic adenocarcinoma –FOLFIRINOX - no response, substantial toxicity Switched to gemcitabine and erlotinib –Again, substantial toxicity –Scans are “stable” in pancreas and liver mets, small  in spleen lesions BRCA testing - negative